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Abstract
Background: We report the feasibility and treatment outcomes of image-guided three-dimensional conformal
arc radiotherapy (3D-CART) using a C-arm linear accelerator with a computed tomography (CT) on-rail system for
localized prostate cancer.
Methods and materials: Between 2006 and 2011, 282 consecutive patients with localized prostate cancer were
treated with in-room CT-guided 3D-CART. Biochemical failure was defined as a rise of at least 2.0 ng/ml beyond
the nadir prostate-specific antigen level. Toxicity was scored according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.0.
Results: A total of 261 patients were analyzed retrospectively (median follow-up: 61.6 months). The median
prescribed 3D-CART dose was 82 Gy (2 Gy/fraction, dose range: 78–86 Gy), and 193 of the patients additionally
received hormonal therapy. The 5-year overall survival rate was 93.9 %. Among low-, intermediate-, and high-risk
patients, 5-year rates of freedom from biochemical failure were 100, 91.5 and 90.3 %, respectively. Rates of grade
2–3 late gastrointestinal and genitourinary toxicities were 2.3 and 11.4 %, respectively. No patient experienced late
grade 4 or higher toxicity.
Conclusions: In-room CT-guided 3D-CART was feasible and effective for localized prostate cancer. Treatment
outcomes were comparable to those previously reported for intensity-modulated radiotherapy.
Keywords: Prostate cancer, Radiotherapy, C-arm
Background
Along with radical prostatectomy and brachytherapy,
external beam radiotherapy (EBRT) with or without
hormonal therapy is one of the most commonly
employed curative treatment options for localized pros-
tate cancer [1–3]. Recent technical developments have
allowed conformal treatment to deliver both high-dose
radiation to the target volume and reduced radiation to
adjacent organs at risk, including the rectum and bladder
[4, 5]. By “conformal treatment,” we mean both image-
guided radiotherapy (IGRT) and high-technology EBRT,
such as three-dimensional conformal radiotherapy
(3D-CRT) and intensity-modulated radiotherapy (IMRT).
As a consequence of these technical developments,
greater effectiveness has been observed in large retro-
spective studies and several prospective randomized trials
of treatment outcomes [6–12]. In fact, dose escalation has
improved local control and cause-specific survival
[13–15]. Moreover, clinical data from the Fox Chase
Cancer Center (Philadelphia, PA, United States) have
suggested that a dose–response relationship exists,
even in the ultra-high dose range beyond 80 Gy [16].
Further, better disease control was obtained with ultra-
high doses, as compared with standard doses [16].
* Correspondence: ohashi@rad.med.keio.ac.jp
1Department of Radiology, Keio University School of Medicine, 35
Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Full list of author information is available at the end of the article
© 2015 Kumabe et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kumabe et al. Radiation Oncology  (2015) 10:208 
DOI 10.1186/s13014-015-0515-4
Although relatively steep dose gradients can be applied
in IMRT, dose escalation is believed to have limited
applicability in 3D-CRT because of treatment-related
morbidities. Several studies have shown correlations
between higher 3D-CRT doses and increased risks of
grade ≥2 late rectal and urinary toxicities [7, 12, 17].
At Sagamihara Kyodo Hospital (Kanagawa, Japan),
image-guided three-dimensional conformal arc radio-
therapy (3D-CART) has been implemented using a
linear accelerator with a computed tomography (CT)
on-rail system for localized prostate cancer since
2004. Dose escalation above 78 Gy (median dose: 82 Gy)
has been investigated without the use of IMRT since 2006.
The CT on-rail system was employed as a tool for IGRT.
As compared with IMRT, our treatment demands less
time, effort and cost for RT planning and verification
because it does not require an inverse-planning
approach. To the best of our knowledge, there have
not been any published reports regarding the clinical
results of 3D-CART for prostate cancer, as applied
with similarly high doses and the use of a CT on-rail
system as an IGRT tool in Japan. The aim of this
retrospective study is to elucidate our method and report
the treatment outcomes and toxicities observed in patients
who received CT on-rail system-guided 3D-CART as a
treatment for prostate cancer.
Materials and methods
Patients
Between January 2006 and December 2011, 282 consecu-
tive patients with T1b-T4N0M0 (International Union
Against Cancer classification, UICC 2002) histologically
proven adenocarcinoma of the prostate were definitively
treated with 3D-CART at Sagamihara Kyodo hospital.
Patients with castration-resistant disease and patients
under treatment for other malignant disease were
excluded. Patients whose follow-up period was less than
2 years were also excluded. A total of 261 patients were
analyzed retrospectively. This study was approved by the
institutional review board of Sagamihara Kyodo hospital.
Patient risk groups were defined following the National
Comprehensive Cancer Network (NCCN) Guidelines.
Patients were classified as follows: i) low risk: stage ≤
T2a, Gleason score ≤ 6, and prostate-specific antigen
(PSA) ≤ 10 ng/ml; ii) high risk: stage ≥ T3, Gleason
score ≥8, or PSA >20 ng/ml; iii) intermediate risk: all
other patients (including patients with stage T2b-T2c,
Gleason score 7, and PSA >10 ng/ml but ≤ 20 ng/ml).
CT-linear accelerator integrated radiation system at our
institution
Figure 1 shows the CT-linear accelerator (linac) inte-
grated radiation system at Sagamihara Kyodo Hospital.
The integrated CT-linac system consists of a linac, a CT
scanner, and a treatment couch, which is shared by both
the linac and CT scanner. The linac gantry and the CT
gantry are set on opposite sides of the treatment couch.
By rotating the treatment couch 180°, patients are able
to undergo both radiotherapy and CT scanning without
having to move by themselves. Radiation treatment sim-
ulations and corrections of the patients’ position before
daily treatment were performed using this in-room CT
system. Radiotherapy was delivered using a C-arm-
mounted linac (CRS-6000, Mitsubishi Electric Corpor-
ation, Tokyo, Japan). As the name indicates, the C-arm
has a C shape, and movement of the gantry head outside
the plane of gantry rotation is realized by attaching the
head to a C-arm. The head moves on the C-arm rail in a
curved path from the vertical position to 60° toward the
gantry (at maximum). In general, other similar linacs
Fig. 1 The CT-linac integrated radiation system at Sagamihara Kyodo Hospital. The C-arm mounted linac is indicated by an arrow
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with a C-arm can deliver radiation and use the C-arm
function only for a small field with a maximal length of
3 cm. At our institution, however, the radiation treat-
ment room was broadly shielded with lead, allowing us
to use this function for larger treatment fields of up to
40 cm. IMRT cannot be performed with the C-arm linac.
Treatment
Radiotherapy was delivered daily, five times per week
with the 6-MV C-arm linac. Simulation was conducted
with the patients in a supine position with a hand-made
support under their knees. All patients underwent a
treatment planning CT scan with a slice thickness of
2 mm, and the resulting images were transferred to a
radiotherapy treatment planning system (Pinnacle,3
Philips Medical Systems, Fitchburg, WI, United States).
Treatment simulation was performed using the CT-linac
integrated system. At the time of CT simulation, patients
were asked to void their bowels and to have a comfort-
ably full bladder by urinating and drinking 500 ml of
water about one hour before the CT scan. They were
asked to do the same before every daily treatment. We
did not introduce any fiducial markers into the prostate.
Instead, prostate calcifications or the prostate itself was
used in setting up patients.
The clinical target volume (CTV) for low-risk patients
consisted of only the prostate, the CTV for intermediate-
risk patients consisted of the prostate and the proximal
half of the seminal vesicles, and the CTV for high-risk
patients consisted of the proximal two-thirds of the sem-
inal vesicles. Although there is potential benefit of
pelvic nodal irradiation in high-risk patients, the
lymph node areas were not included in the CTV,
because we were unsure regarding the clinical benefit
and the toxicity associated with a high dose of RT of
above 78 Gy. The planning target volume (PTV) was
obtained by adding a 5-mm margin in all directions,
including the posterior aspect of the prostate.
An additional 5-mm margin was added around the
PTV to account for the penumbra. The beam arrange-
ment was as follows: 360°-conformal arc (181° to 180°),
right lateral (90°), and left lateral (270°). The lateral two
ports were non-coplanar; they were inclined 15° from
the same plane, such that the C-arm function of the gan-
try head could be used to exclude the femoral heads
from the treatment field without shifting the treatment
couch. These two fields were blocked with a multi-leaf
collimator such that the treatment field did not include
more than 5 mm of the anterior rectal wall. Figure 2a
shows a typical dose distribution, and Fig. 2b shows a
dose-volume histogram of 3D-CART for a patient
treated to a total dose of 84 Gy. The treatment dose was
prescribed to the isocenter. The rectum (from the anal
verge to the sigmoid flexure) and the entire bladder were
delineated as the organs at risk. Table 1 shows the dose-
volume relationships for the PTV, rectum, and bladder.
Before treatment, each patient underwent a CT exam-
ination of the pelvis, and the couch shared by the CT
and linac was rotated 180° toward the linac. Subse-
quently, the patient’s position was corrected according
to the image in the setting of the simulation. The CT
images taken before treatment and from the simulation
were compared side-by-side on the monitor. After im-
aging performed using in-room CT, image registration
was done manually. Patients underwent 39 to 43 add-
itional CT scans throughout the treatment course. With
Fig. 2 A typical dose distribution (a) and dose-volume histogram (b) for three-dimensional conformal arc radiotherapy. In the left panel, the thick
red line circumscribes 95 % of the prescribed dose. PTV, planning target volume
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regard to additional doses due to the daily IGRT proto-
col, the physicians at our department estimated the ap-
proximate additional dose received by the patient as
34 cGy over 40 fractions. According to the report from
the American Association of Physicists in Medicine Task
Group 179 [18], the imaging dose per scan from kV-
CBCT ranged from 0.1 to 2 cGy, meaning that the total
additional dose for 40 fractions of treatment is expected
to range from 4 to 80 cGy. This additional dose using
our IGRT method is comparable to the dose from kV-
CBCT. Although this additional dose is not negligible,
the potential benefit of using the IGRT technique was
thought to justify any risks to the patient.
In practice, neoadjuvant androgen deprivation therapy
(ADT) was administered to intermediate- and high-risk
patients for 6 months. Additionally, adjuvant ADT was
administered to high-risk patients for 2–3 years. Because
of the retrospective nature of this study, however, the
use and period of ADT were determined according to
the discretions of the physicians involved and consensus
with the patient.
Follow-up and oncological outcomes
During the course of irradiation, patients were examined
weekly by radiation oncologists. Post-treatment clinical
follow-up and PSA examinations were generally per-
formed at 3-month intervals for the first 2 years after
treatment and every 6 months thereafter. We evaluated
freedom from biochemical failure (FFBF) according to
the Phoenix criteria; biochemical failure was defined as a
rise of at least 2.0 ng/ml beyond the PSA nadir [19].
Toxicity was evaluated according to the National Cancer
Institute Common Terminology Criteria for Adverse
Events (NCI-CTCAE), version 4.0. Acute toxicities were
defined as those occurring during the course of radio-
therapy (RT) or within 90 days of its completion. Late
toxicities were defined as those occurring thereafter.
Statistical analysis
According to the clinical outcomes, FFBF and overall
survival (OS) were calculated using the Kaplan-Meier
method. The statistical significance of differences between
survival curves was examined using the log-rank test. All
times to events were measured from the initiation of RT.
The statistical analysis was performed using SPSS version
22.0 (IBM Corporation, Armonk, NY, United States).
Results
Patients
The patients’ characteristics are listed in Table 2, includ-
ing tumor stage, pretreatment PSA value, Gleason score,
risk group, prescribed dose, and the use of hormonal
Table 1 Dose-volume relationships for the planning target volume, rectum, and bladder for 261 patients
Patients IC dose D95 (PTV) V80R V70R V50R V80B V70B V50B
(Gy) (Gy) (%) (%) (%) (%) (%) (%)
median 82 75.9 0.4 6.7 24.5 5.5 12.2 22.2
range 78–86 70.8–80.9 0–3.2 3.0–11.2 12.1–42.2 0–18.9 2.8–30.7 7.8–50.5
PTV planning target volume, IC isocenter, D95(PTV) the dose given to 95 % of the PTV; V80R, V70R, and V50R, percent of the volume of the rectum receiving
80 Gy, 70 Gy, and 50 Gy, respectively; V80B, V70B, and V50B, percent of the volume of the bladder receiving 80 Gy, 70 Gy, and 50 Gy, respectively
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therapy. Of the 261 analyzed patients, 42, 95, and 124
were low-, intermediate-, and high-risk, respectively.
The median total dose was 82 Gy (range, 78–86 Gy),
and the daily fractional dose was 2 Gy.
Outcomes
The median follow-up period was 61.6 months (range,
29.5–107.3 months). FFBF rates are shown in Fig. 3,
as stratified by NCCN risk classification (p = 0.117).
The 5-year FFBF rates for low-, intermediate- and
high-risk patients were 100, 91.8, and 90.3 %, respectively.
No patient died of prostate cancer. Fifteen patients died of
other causes during the follow-up period. Of these pa-
tients, 10 patients succumbed to other malignant diseases,
and 5 died as a result of other non-neoplastic diseases
(e.g., acute coronary syndrome, pneumonia, and mesen-
teric thrombosis). Figure 4a shows the OS for all patients
(5-year OS rate, 93.9 %) and Fig. 4b shows the OS strati-
fied by NCCN risk classification (p = 0.164).
Toxicity
Acute and late gastrointestinal (GI) and genitourinary
(GU) toxicities are summarized in Table 3. Acute GI
toxicity was observed in 26.8 % of patients and included
anal pain at defecation, anal discomfort, soft stool, and
anal bleeding. Acute GU toxicity was more common, oc-
curring in 75.9 % of patients. By 90 days after treatment,
19.2 % patients had developed grade 2 GU urinary
symptoms, which were often treated with oral medi-
cations (e.g., an alpha blocker or Japanese Kampo).
All of the observed acute toxicities were transient. No
grade ≥3 acute toxicity was observed.
In regard to late GI adverse events, grade 2 and grade
3 toxicities were observed in 1.9 and 0.4 % of patients,
respectively. The observed late GI toxicities were rectal
bleeding and fecal urgency. One patient developed grade
3 rectal bleeding, which required endoscopic coagulation
therapy. In regard to late GU adverse events, grade 2
and grade 3 toxicities were observed in 10.3 and 1.1 % of
patients, respectively. The observed late GU toxicities
were chronic urinary frequency, urgency, incontinence,
urethral stricture, and transient urinary bleeding. Three
patients developed grade 3 urethral stricture, which
required urethral dilation. No grade ≥4 late toxicity was
observed.
Discussion
This study reports the clinical results of definitive treat-
ment with CT-guided 3D-CART in patients with localized
prostate cancer. The clinical outcomes and the treatment-
related toxicity profile that we observed during the follow-
up period (median, 61.6 months) appeared favorable in
comparison with previous reports of IMRT [20–22]. To
the best of our knowledge, this is the only report regarding
the use of CT on-rail system-guided 3D-CART to deliver
high doses (median dose: 82 Gy) for patients with prostate
cancer in Japan. Further, in previously published Japanese
studies of EBRT for prostate cancer, the prescribed doses
have all been under 80 Gy [23–25].
With the development of EBRT, high-dose radiotherapy
has become a well-established treatment for localized
Fig. 3 Kaplan-Meier estimates of freedom from biochemical failure, as stratified by NCCN risk. Biochemical failure was defined as a rise of at least
2.0 ng/ml beyond the prostate-specific antigen nadir
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prostate cancer. In several randomized trials and a meta-
analysis, comparisons of high- and low-dose RT have
shown that high doses offer significant improvements in
biochemical control [11, 12, 26]. Moreover, the findings of
some studies have suggested that doses in the ultra-high
range (beyond 80 Gy) offer clinical benefit in the form of
disease control [16, 20, 27].
Despite the clinical benefits that are offered by dose
escalation, the delivery of high-dose RT to the prostate
is associated with elevated rates of GI and GU toxicities.
The toxicities reported in previous studies of EBRT are
summarized in Table 4. Studies that employed 3D-CRT
with doses exceeding 74 Gy showed rates of treatment-
related grade ≥2 GI and GU toxicities of 5.5–26 and
2.9–28 %, respectively [6–8, 11, 12]. In a randomized
trial of 3D-CRT from the M.D. Anderson Cancer Center
(Houston, TX, United States), Kuban et al. showed that
the rate of grade ≥2 late GI complications was twice as
high in patients treated to 78 Gy than in patients treated
to 70 Gy (26 % versus 13 %, respectively) [12]. Michalski
et al. conducted a multi-institutional dose-escalation
phase I–II study of 3D-CRT (RTOG 9406) and reported
that grade ≥2 late GI and GU toxicities occurred in
25–26 and 23–28 % of patients, respectively, with a
dose of 78 Gy in 39 fractions [8]. Reports of dose
escalations above 74 Gy using IMRT have shown rates of
grade ≥2 GI and GU toxicities of 2.4–18 and 3.5–22 %, re-
spectively [20–22]. In a retrospective analysis from the
Memorial Sloan Kettering Cancer Center (New York, NY,
United States), Spratt et al. reported that grade ≥2 late GI
and GU toxicities occurred at incidences of 4.4 and
21.1 %, respectively, in patients who had undergone IMRT
to a total dose of 86.4 Gy (1.8 Gy/fraction) [20]. Eada et al.
showed that grade ≥2 GI and GU toxicities occurred in
2.4 and 3.5 % of patients, respectively, following IMRT
with a total dose of 74–78 Gy (2 Gy/fraction) [21].
Comparing the complication rates associated with
IMRT and 3D-CRT, GI toxicity rates are generally
lower for IMRT [10, 28, 29].
In the current study, rates of grade 2 late GI and GU
toxicities were 1.9 and 10.3 %, respectively, and rates of
grade 3 late GI and GU toxicities were 0.4 and 1.1 %,
respectively. There is a striking variation in the toxicity
rates that have been reported across different studies.
The large variation probably results from differences in
treatment methods, radiation doses, and toxicity as-
sessments. Notably, there is no single, standardized
tool for measuring treatment-related toxicity. Even
when we consider these between-study differences,
our results for 3D-CART are comparable to those
previously reported for IMRT, although we prescribed
high doses (78–86 Gy) and employed a non-IMRT
technique. There are several potential explanations for
this result, as described below.
First, our approach reduced the volume of the rectum
that was exposed to high-dose radiation, as compared
with conventional 3D-CRT approaches such as the static
five-to-seven port technique. In our 3D-CART approach,
the rectal volume that was exposed to high doses (V80R,
V70R) compares favorably with that of IMRT (Table 1
Fig. 4 Kaplan-Meier estimates of overall survival for all patients (a) and as stratified by NCCN risk (b)
Table 3 Incidences of gastrointestinal and genitourinary acute
and late toxicities (n = 261)
Grade GI toxicity n (%) GU toxicity n (%)
Acute Late Acute Late
1 64 (24.5) 26 (10.0) 148 (56.7) 37 (14.1)
2 6 (2.3) 5 (1.9) 50 (19.2) 27 (10.3)
3 0 1 (0.4) 0 3 (1.1)
GI gastrointestinal, GU genitourinary
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and Fig. 2). Our treatment planning method could have
contributed to the low frequency of late rectal toxicities.
Second, we used a linac with CT on-rail system as an
IGRT tool in daily treatment sessions. Consequently, we
were able to confirm that the target was enclosed in the
treatment field before every RT session.
Third, we were able to reduce the margins using this
IGRT technique. IGRT is believed to be the best method
of reducing margins. Sveistrup et al. [30] reported the
toxicity rates in patients treated with image-guided
IMRT and 3D-CRT without daily image guidance. Three
hundred eighty-eight patients were treated at a dose of
78 Gy using IMRT, based on daily image guidance with
fiducial markers. Further, 115 patients were treated at a
dose of 76 Gy using 3D-CRT without daily image guid-
ance. The 2-year rates of grade ≥2 GI toxicity were 5.8
and 57.3 % in the patients treated with image-guided
IMRT and 3D-CRT, respectively (p < 0.001). Regarding
GU toxicity, the corresponding values were 29.7 and
41.8 %, respectively (p = 0.011). In a study of IGRT and
non-image guided RT, Zelefsky et al. [31] found that
IGRT was associated with improved biochemical tumor
control in high-risk patients, as well as a lower rate of
late urinary toxicity in the total patient cohort.
In the present study, we set a 5-mm margin for the
CTV in all directions, which is smaller than the margins
reported previously [8, 20, 21, 23, 27]. As a tool for
IGRT, the CT on-rail system provides better image qual-
ity than is obtainable using cone-beam CT, which is
often equipped with the latest linacs. Therefore, we
attempted to set up patients using prostate calcifications
or the prostate itself as markers in daily IGRT, without
implanting artificial fiducial markers (i.e., gold markers).
Fourth, we reduced the prescribed dose by 2–4 Gy in
patients who were thought to have possible risk factors
for late toxicities (i.e., use of anticoagulants, diabetes, or
the occurrence of severe acute toxicities). This thera-
peutic strategy may also have reduced late toxicities.
Considering the risk of toxicities due to the RT, however,
78 Gy remains a high dose for patients with such co-
morbidity factors. In hindsight, lower doses should have
been used in such patients.
A small PTV margin could leave the target out of the
radiation fields, worsening the results of treatment. In
our study, however, the 5-year FFBF rates for low-, inter-
mediate-, and high-risk patients were 100, 91.8, and
90.3 %, respectively. Although 15 patients died during
the follow-up period, no patient died of prostate cancer
and the 5-year OS rate was 93.5 %. These outcomes
compare favorably with those of previous reports on
IMRT. Our results indicate that high-accuracy position-
ing with IGRT can allow small PTV margins to be used
in EBRT for prostate cancer.
As compared with IMRT, our therapy demands less
time and effort for RT planning and verification because
it does not require an inverse-planning approach. In
order to ensure accurate dose delivery, IMRT requires
meticulous implementation and execution with rigorous
quality assurance and control. In Japan, two or more
full-time radiation oncologists and one or more full-time
radiation physicists are needed for IMRT at each radi-
ation therapy facility. However, many institutions do not
fulfill these criteria owing to a lack of human resources,
and they are therefore not allowed to implement IMRT.
At our institution, we performed the 3D-CART tech-
nique routinely in daily RT sessions for patients with
localized prostate cancer patients, without encountering
any difficulty. This method saved time during preparation
before RT—in fact, RT began two days after planning CT
imaging. Considering the clinical outcomes and ease of
preparation before RT, the reported approach may provide
another treatment choice for prostate cancer patients.
Table 4 Overview of reported late toxicities in EBRT for localized prostate cancer




GI toxicity (%) GU toxicity (%) Grading
scale
Follow-up









Present study 261 78–86 3D-CRT 0.5 (0.5) 1.9 0.4 10.3 1.1 CTCAE4.0 61





220 78 25–26 23–28 71–73
Ikeda et al. [24] 150 74 3D-CRT 0.6 (0.9) 5.5, Grade 2/3 2.9, Grade 2/3 RTOG/EORTC 89
Kuban et al. [12] 151 78 3D-CRT - (box four field) 19 7 7 3 RTOG/LENT 61
Spratt et al. [20] 1002 86.4 IMRT 0.6 (1.0) 4.4, Grade 2/3 21.1, Grade 2/3 CTCAE4.0 63
Eade et al. [21] 216 74–78 IMRT 0.5–0.6 (0.8) 2.4 0 3 0.5 RTOG 48
De Meerleer et al.
[22]
133 74–76 IMRT 0.7 (1.0) 17 1 19 3 RTOG 36
EBRT external beam radiotherapy, 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, RTOG radiation therapy oncology
group, LENT late effects normal tissue task force, CTCAE common terminology criteria for adverse events
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The key limitations to this study are its retrospective
nature and the differences in the toxicity assessment
methods that were employed by each radiation oncologist.
However, it should also be considered that few patients
suffered from severe late treatment-related toxicity during
the follow-up period (median duration, 61 months), des-
pite the application of high-dose RT (78–86 Gy). Further,
the initial treatment results are comparable to previous
reports of IMRT dose escalation studies, although a direct
comparison between the 3D-CART approach and IMRT
would of course be necessary to reach definitive con-
clusions. Longer durations of follow-up will be needed
to provide a full evaluation of the treatment results,
especially for patients who received adjuvant hormo-
nal therapy for long periods. Additionally, given the
inclusion of low-risk patients and the absence of
deaths from prostate cancer, the study’s results could
have been affected by overdiagnosis to some extent,
since the outcomes of overdiagnosed patients would
not reflect the actual benefits of RT.
Conclusions
In conclusion, this report confirmed the feasibility and
effectiveness of high-dose (≥78 Gy) conformal arc radio-
therapy in a large cohort of patients with prostate cancer.
The treatment outcomes were comparable to those that
have previously been reported for IMRT. In this retro-
spective study, we found that the 3D-CART approach with
IGRT using a CT on-rail system was associated with a low
frequency of late rectal toxicities.
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